13 Recruiting Endometrial Cancer Phase 3 Clinical Trials
Active phase 3 studies for endometrial cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Endometrial Cancer studiesPhase 3 Studies for Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
📍 USA Mitchell Cancer Institute ( Site 4142) — Mobile, Alabama
View Study & Checklist ➔Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
📍 Canberra Hospital — Garran,
View Study & Checklist ➔Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
📍 The University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
📍 University of South Alabama, Mitchell Cancer Institute ( Site 6033) — Mobile, Alabama
View Study & Checklist ➔Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
📍 Kaiser Permanente Center — Vallejo, California
View Study & Checklist ➔A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
📍 Yale University School of Medicine — New Haven, Connecticut
View Study & Checklist ➔DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
📍 Research Site — Tucson, Arizona
View Study & Checklist ➔Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
📍 Research Site — Tucson, Arizona
View Study & Checklist ➔Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
📍 The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto — Toronto,
View Study & Checklist ➔Vaginal Cuff Brachytherapy Fractionation Study
📍 University of Maryland Medical Center (UMMC) — Baltimore, Maryland
View Study & Checklist ➔Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
📍 Broward Health Medical Center — Fort Lauderdale, Florida
View Study & Checklist ➔Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
📍 USAH Mitchell Cancer Inst — Mobile, Alabama
View Study & Checklist ➔